Laboratory automation is increasing the need for specimen collection systems that integrate efficiently with downstream processing and testing workflows. Standardized tubes, labels, transport systems, and compatible collection devices can improve laboratory efficiency. Greater automation is encouraging manufacturers to develop products suited to modern diagnostic environments.

The Bacterial and Viral Specimen Collection Market has become an essential component of the global infectious disease diagnostics ecosystem. Accurate diagnosis begins with obtaining a suitable specimen, making collection devices, transport media, swabs, tubes, and other sample-management products critical to laboratory testing.

The Bacterial and Viral Specimen Collection Market is expected to register a CAGR of 14.70% from 2025 to 2031, with a market size expanding from US$ 26.77 Billion in 2024 to US$ 69.91 Billion by 2031.

The market is benefiting from the increasing use of molecular diagnostics, rising infectious disease surveillance, growing demand for rapid testing, and the expansion of decentralized healthcare. Advances in PCR, multiplex molecular assays, and other high-sensitivity diagnostic platforms are increasing the importance of specimen quality and appropriate sample handling.

Current CDC guidance emphasizes that specimen collection is an important part of infectious-disease testing and that the choice and handling of specimens can affect diagnostic performance.

Competitive Landscape

The competitive environment includes diagnostic companies, laboratory technology providers, specimen-collection specialists, and manufacturers of transport and sample-preservation products.

Key companies operating in the market include:

• Fisher Scientific
• Quidel Corporation
• QIAGEN N.V.
• WuXi Nest Biotechnology Co., Ltd.
• DiaSorin S.p.A
• Titan Biotech Ltd
• Spectrum Solutions LLC
• Becton Dickinson and Company
• COPAN Diagnostic Inc.
• Longhorn Vaccines and Diagnostic LLC

Competition is increasingly shifting from basic collection products toward integrated sample-to-answer workflows. Companies are focusing on specimen integrity, contamination control, transport stability, compatibility with molecular platforms, and convenience for healthcare professionals and patients.

The growing adoption of molecular diagnostics is particularly important because these systems often require specimens that meet specific collection, transport, and processing requirements.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00033007

Molecular Diagnostics Drive Demand for High-Quality Specimens

The rapid expansion of PCR and other nucleic-acid-based technologies is one of the strongest growth drivers for the specimen collection market.

Molecular tests can detect pathogen genetic material with high sensitivity, but their performance depends partly on obtaining and preserving an appropriate clinical sample. CDC guidance notes that molecular assays can detect influenza viral RNA for longer periods than some other testing approaches, while proper handling and manufacturer instructions remain important for achieving optimal performance.

As molecular testing expands across hospitals, reference laboratories, physician offices, and decentralized settings, demand is increasing for collection systems compatible with these workflows.

This trend is encouraging manufacturers to develop collection devices designed to improve sample consistency, simplify processing, and maintain specimen stability during transportation.

Multiplex Testing Changes Specimen Collection Requirements

Multiplex diagnostics are becoming increasingly important in infectious disease testing because a single assay can identify multiple pathogens from one clinical specimen.

Respiratory testing provides a clear example. Current CDC guidance recommends multiplex nucleic-acid testing for influenza A/B and SARS-CoV-2 in certain clinical circumstances when available.

The FDA has also classified molecular multi-analyte respiratory-virus tests that detect and differentiate multiple respiratory viruses directly from clinical specimens.

This evolution can increase demand for collection systems capable of supporting multiple downstream assays. Instead of collecting separate specimens for every suspected pathogen, healthcare providers can increasingly rely on multiplex workflows where appropriate.

For manufacturers, this creates opportunities to develop universal or multi-platform collection systems that can accommodate evolving diagnostic technologies.

Respiratory Infections Remain a Major Application Area

Respiratory infections represent a significant application for bacterial and viral specimen collection products.

Seasonal influenza, RSV, COVID-19, and other respiratory infections continue to require laboratory surveillance and diagnostic testing. The simultaneous circulation of respiratory viruses can make pathogen identification particularly important for treatment decisions and infection-control measures.

CDC guidance published in 2026 specifically addresses specimen collection and testing when SARS-CoV-2, RSV, and influenza viruses are circulating simultaneously.

Nasopharyngeal, nasal, and other respiratory specimens are therefore expected to remain important product categories, while manufacturers increasingly focus on patient comfort, collection accuracy, transport stability, and compatibility with rapid molecular testing.

Decentralized and At-Home Collection Expand the Market

Diagnostic testing is increasingly moving closer to the patient.

Point-of-care testing, physician-office testing, urgent-care facilities, pharmacies, and at-home testing are creating new requirements for specimen collection products that can be used outside traditional laboratories.

The FDA has established a device classification for over-the-counter molecular multi-analyte respiratory-virus tests intended for use directly by consumers in home settings.

This development highlights an important shift in the market: specimen collection is no longer exclusively a laboratory-centered process.

Products that are easy to use, reduce collection errors, minimize discomfort, and maintain sample integrity could gain greater adoption as decentralized diagnostics expand.

Specimen Transport and Stability Become Competitive Priorities

Collection is only the first stage of the diagnostic workflow. Once a sample has been obtained, it may need to be transported to a laboratory while maintaining its integrity.

Transport media, stabilization solutions, temperature requirements, and storage conditions can influence the reliability of downstream testing. CDC guidance recommends following test-specific requirements for specimen handling and transport, including appropriate transport media and minimizing conditions that can degrade specimens.

This creates opportunities for manufacturers to develop improved transport systems that extend stability, simplify logistics, and support testing across centralized and decentralized laboratory networks.

Emerging Technologies Improve Collection Efficiency

Automation and digitalization are also influencing specimen management.

Laboratories are increasingly seeking standardized collection workflows that can reduce manual handling and improve traceability. Barcode-based identification, electronic sample tracking, automated accessioning, and laboratory information-system integration can reduce the possibility of specimen errors.

At the same time, manufacturers are exploring collection devices designed for specific molecular platforms and sample types.

These developments support a broader industry shift toward standardized, connected, and efficient diagnostic workflows.

Future Outlook

The future of the Bacterial and Viral Specimen Collection Market will be strongly influenced by the continued expansion of molecular diagnostics, multiplex testing, decentralized healthcare, and infectious disease surveillance.

Collection products are likely to become increasingly integrated with complete diagnostic workflows. Manufacturers will focus on improving specimen quality, simplifying collection procedures, extending sample stability, and supporting compatibility with multiple testing platforms.

The rise of at-home molecular testing could create another important growth pathway. As more diagnostic decisions move closer to the patient, collection products will need to become simpler and more intuitive while maintaining the quality required for sensitive laboratory methods.

Multiplex testing is also expected to remain a key trend, particularly for respiratory pathogens and syndromic infectious disease panels. Recent FDA clearances for multi-target respiratory nucleic-acid tests demonstrate continued innovation in this area.

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish

Related Reports:

Agricultural Genotyping Market Growth, Size & Forecast by 2034

IVD Devices Contract Manufacturing Market – Trends, Growth & Opportunities

About Us

The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.

Contact Us

Contact Person: Ankit Mathur

Phone: +1-646-491-9876

E-mail : sales@theinsightpartners.com